PolymarketKapalıKullanılabilirliği kontrol etKYC yok%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreBu piyasa sonuçlandı: Yes
Sonuçlandı: 28 Haz 2026 23:21
Sağlayıcı tarafından doğrulanmış sonuç
CoinRithm bu piyasa için kazanan ve sonuçlanma zamanı konusunda sağlayıcı destekli kanıta sahip.
Kazanan Sonuç
Yes
7 gün kala
—
24 saat kala
—
Güncel ima edilen olasılık
Evet 100%+0.0pt
Piyasa kalitesi
≤49 / 100
Düşük kalite24s Hacim
₺270,4 B
Likidite
—
Likidite bilinmiyorAlış / Satış
99.9% / 100.0%
Spread
0.1 pt
Dar spread7g Değişim
+26.9 pts
Piyasa verileri
64 gün önce güncellendi
Guncelligini yitirmis4 Haz 26 19:5430 Haz 26 0:00
Olasılık Zaman Çizelgesi
No0%
Yes100%
100%
0%
Kurallar
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
